Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ivantis, Inc.
After decades without an approval pathway for excipients, FDA pilot program paves the way for innovation.
A proposed change to US Medicare billing that would go into effect 1 January might give one manufacturer an edge over its competitor.
Glaukos Corp. said it expects rising competition in the US microinvasive glaucoma surgery (MIGS) space in 2020 from Ivantis along with surgical procedures.
In the randomized COMPARE trial, eyes treated with Ivantis' Hydrus Microstent were about twice as likely to not need medication than eyes treated with two Glaukos iStent trabecular micro-bypass stents one year after implant The one-year results of the trial have been accepted for publication in Opthalmology.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive